UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C.20549
_____________
FORM 8-K/A
Amendment No. 1 to
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): December 29, 2011
_____________
Manhattan Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
Delaware (State or other jurisdiction of incorporation) | 001-32639 (Commission File Number)
| 36-3898269 (IRS Employer Identification No.) |
787 Seventh Ave, 48th Floor
New York, New York 10019
(Address of principal executive offices)
(212) 554-4305
(Registrant's telephone number, including area code)
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
| 99.1 | Audited Consolidated Financial Statements of Manhattan Pharmaceuticals, Inc. |
| 99.2 | Unaudited Pro Forma Condensed Consolidated Financial Statements of Manhattan Pharmaceuticals, Inc. |
| -2- |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Manhattan Pharmaceuticals, Inc. | |||
| (Registrant) | |||
| Date: March 16, 2012 | By: | /s/ Sean A. Power | |
| Sean A. Power | |||
| Chief Financial Officer, Treasurer and Secretary | |||
| -3- |